🤯 Picked by our AI, this stock rallied more than Nvidia this month, yielding 94% since MarchSee the stock

Stifel raises Virbac share price target citing strong Q1 and Sasaeah acquisition impact

EditorEmilio Ghigini
Published 04/17/2024, 09:33 AM
VIRB
-

On Wednesday, Stifel adjusted its financial outlook for Virbac SA (VIRP:FP) (OTC: VRBCF), a veterinary pharmaceutical company, by increasing the share price target to €369.00 from the previous €349.00.

Despite the price target change, the firm maintained its Hold rating. This revision follows Virbac's announcement of a robust first quarter, with like-for-like sales growing by 9.7%, significantly propelled by a 16.2% increase in the companion animal segment.

The sales growth in the companion animal division was attributed primarily to a roughly 6.4 percentage point surge from volume expansion, supplemented by a modest price effect. The latter was mainly due to a deceleration in inflation rates. Virbac has confirmed its financial guidance for the year 2024, staying on course with its previously stated expectations.

The revision to Stifel's assessment includes the recent acquisition of Sasaeah, a Japanese firm, which was completed earlier in the month. This new business venture is anticipated to contribute over four percentage points to Virbac's revenue growth in 2024.

The acquisition's impact, coupled with a stronger-than-expected top-line performance, has led Stifel to revise its forecasts upwards, with an increase in estimated earnings per share (EPS) by 11% and 18% for 2024 and 2025, respectively.

The updated price target of €369 reflects an increase of €20 from the former target, based on the positive first-quarter trading update and the expected revenue contributions from the Sasaeah acquisition. The new price target takes into consideration the upward revisions to both revenue and EPS forecasts for the coming years.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.